Latest 10-Q quarterly reports

Inhibrx Biosciences reported continued progress in its clinical pipeline for ozekibart and INBRX-106, alongside a significant increase in long-term debt and ongoing net losses for the second quarter of 2026.

Serina Therapeutics, Inc. reported a net loss of $6.36 million for the quarter ended June 30, 2026, and faces substantial doubt about its ability to continue as a going concern.

Revium Rx reports continued R&D progress in its Nano-Mupirocin program but faces significant financial challenges, including a substantial accumulated deficit and doubts about its going concern status.

Fennec Pharmaceuticals Inc. announced robust second quarter 2026 financial results, driven by a 78% year-over-year increase in PEDMARK net product sales and a significant improvement in Adjusted EBITDA.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reported its Q2 2026 results, highlighting the completion of its merger with Yarrow and a continued focus on its lead candidate YB-101, while managing significant accumulated deficits and future funding needs.

NextNRG, Inc. filed its Q2 2026 report, showing increased revenues but also significant net losses and a substantial working capital deficit, highlighting ongoing financial concerns.

Northpointe Bancshares, Inc. announced a significant increase in net income available to common stockholders for the second quarter of 2026, driven by growth in its Mortgage Purchase Program and All-in-One loan portfolios.

RenX Enterprises Corp. filed its Q2 2026 Form 10-Q, detailing a significant increase in revenue driven by its logistics and compost sales segments, but also reporting substantial net losses and a growing accumulated deficit.

Vivani Medical, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued operating losses and a need for further financing, while also announcing progress on clinical trials and a proposed merger for its Cortigent subsidiary.

Gouverneur Bancorp, Inc. announced improved net income and net interest income for the nine months ended June 30, 2026, alongside a strategic initiative to optimize its balance sheet by selling securities and loans to reinvest in higher-yielding assets.

Gossamer Bio announced the reacquisition of global rights to seralutinib from Chiesi, alongside a significant debt restructuring and a substantial net loss for the quarter.

RRE Ventures Acquisition Corp. reports on its Q2 2026 performance, detailing the successful completion of its Initial Public Offering and the subsequent management of funds held in trust.

RCM Technologies, Inc. announced its Form 10-Q filing for the quarter ended July 4, 2026, showcasing significant revenue increases across key segments and improved net income.

Bluerock Homes Trust, Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing a net loss and increased expenses, though revenue saw a notable increase.

FB Bancorp, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a decrease in net income from continuing operations, driven by higher non-interest expenses, despite an increase in non-interest income.

The VanEck Bitcoin ETF experienced a substantial decrease in Net Asset Value and Net Asset Value per Share during the six months ended June 30, 2026, primarily driven by a significant decline in the price of Bitcoin.

The VanEck Ethereum ETF experienced a substantial decrease in Net Asset Value and per-share value during the six months ended June 30, 2026, primarily driven by a sharp decline in the price of Ether.

eXoZymes Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational cash burn, leading to substantial doubt about its ability to continue as a going concern.

JFB Construction Holdings announced a substantial increase in revenue for the six months ended June 30, 2026, driven by larger real estate development projects, but also reported a widening net loss due to increased operating expenses.

The VanEck Avalanche ETF reported a decrease in net assets for the quarter ended June 30, 2026, primarily driven by a significant drop in the price of Avalanche (AVAX), despite an increase in outstanding shares and staking income.

KBS Real Estate Investment Trust III, Inc. (KBS REIT III) reported its Q2 2026 results, highlighting substantial debt and ongoing market challenges that raise going concern issues.

Vystar Corporation's Q2 2026 Form 10-Q filing reveals a significant revenue decrease and continued net losses, raising substantial doubt about its going concern status.

Stark Focus Group Inc. filed its Q2 2026 10-Q, detailing a significant change in control, debt extinguishment, and a pivot towards data center development, while reporting no revenue and facing going concern issues.

Creatd, Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing significant net losses and a going concern warning, alongside strategic divestitures and operational adjustments.

Travelzoo's Q2 2026 results show a revenue decline in Advertising and Commerce, offset by growth in Membership Fees, alongside increased sales and marketing expenses.

Lumexa Imaging Holdings, Inc. announced a significant increase in total revenues and a return to profitability for the six months ended June 30, 2026, compared to the same period in 2025.

Skinvisible, Inc. filed its Q2 2026 10-Q, revealing continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, though progress is noted in licensing and regulatory pathways.

USANA Health Sciences reported a net loss of $21.4 million for the second quarter of 2026, impacted by a $29.1 million goodwill impairment charge for its Hiya segment and declining sales in its Core Nutritional business.

AltEnergy Acquisition Corp. reports continued operational losses and a significant accumulated deficit, with no business combination yet secured, raising substantial going concern doubts.

Sundance Strategies, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting no revenue and a net loss of $213,145, while highlighting ongoing liquidity concerns and significant related-party debt.